Tomeko is an AI-supported digital health ecosystem operated by Tomeko LLC. We connect disease information, specialists, treatments, research, clinical trials, patient organizations, resources and communities — so the next family doesn’t have to navigate it alone.
For families facing a rare or complex illness, the hardest part is often the not-knowing. Patients see specialist after specialist, repeat the same tests, and lose months — sometimes years — before anyone can name what is wrong. Every one of those months is time without answers, without the right care team, and without a community that understands.
Tomeko was built by a family living through four generations of rare disease. Our purpose is straightforward — to shorten the distance between a symptom and an answer, and between a diagnosis and the right care. Tomeko brings the specialists, research, clinical trials, treatments and community for each condition into one living place, for the rare and chronic disease communities alike.
Tomeko is a disease intelligence network — a connected set of smart pages for the rare and chronic disease community. Each disease page pulls together the right specialists, open clinical trials, current research, patient organizations, and community, and is designed to be most useful in the moment people need it most: the first hours and days after a diagnosis. Patients, families, and clinicians all meet on the same page.
Tomeko is operated by Tomeko LLC, an independent company — not a nonprofit, and we don’t fundraise or take donations. Over time, we intend to convert Tomeko to a Public Benefit Corporation — a structure that legally binds our public mission (benefit to rare and chronic disease patients and families) to the company itself.
We will never take outside investors. Tomeko is independent by design. It is funded by the organizations that need to reach the community — sponsors, health systems, industry, and grants — never by venture capital, never by selling patient data, and never by charging patients. That independence is the whole point: doing right by patients can never be outvoted by a cap table.
We stay free for patients through labeled, editorially-firewalled sponsorship, and we partner with the nonprofits and foundations who own each disease community — we don’t replace them.
Eden Lord is the founder of Tomeko. She has worked in rare disease for fifteen years — and has lived it across four generations of her own family as a caregiver. She built Tomeko on one conviction: that families facing a rare or chronic diagnosis deserve a single place they can trust — to find care, research, organizations, and one another — with nothing sold and no data taken.
Her career spans education, public service, and rare-disease strategy. She has designed curriculum for five universities over two decades, worked in journalism, and served with the U.S. Army Corps of Engineers. She holds a BA in economics and an MS in organizational management, and writes on rare-disease navigation and AI literacy.
Last updated August 30, 2026.